THE increasing enthusiasm for treating thromboembolic diseases with prothrombin-reducing drugs for long periods in ambulatory patients has emphasized the lack of clear definition of the therapeutic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results